Provided herein are in vitro methods for diagnosing an immediate hypersensitivity reaction (IHR) against a small compound or a drug in a subject, comprising the steps of (a) contacting mast cells with serum obtained from said subject; (b) contacting the mast cells obtained in step (a) with said small compound or said drug; (c) detecting mast cell activation and/or degranulation of the mast cells obtained in step (b); and (d) attributing the detection or no detection of mast cell activation and/or degranulation to a particular diagnosis of IHR.

The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

This document provides methods and materials involved in identifying and treating autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy, a novel meningoencephalomyelitis, in humans as well as methods and materials for identifying and offering early treatment for patients having autoimmune GFAP astrocytopathy whose autoantibody profile predicts a high likelihood of having underlying cancer (e.g., adenocarcinoma or teratoma).

The presently claimed invention relates to materials and methods for diagnosing a chronic inflammatory disease in a patient comprising testing a biological sample from the patient for a level of a first neurovascular biomarker of lymphatic activation and diagnosing the patient as having the chronic inflammatory disease if the tested level of the first neurovascular biomarker of lymphatic activation is less than a first normal level.

An object of the present invention is to provide a novel method for detecting an allergic disease (for example, allergic rhinitis or allergic conjunctivitis) and an activation state of mast cells and/or eosinophils, and a novel method for determining a therapeutic effect on an allergic disease. The present invention provides a method for detecting an allergic disease or an activation state of mast cells and/or eosinophils in the nasal cavities or eyes, comprising the step of measuring the concentration of a lipid metabolite in a biological sample of a subject. The present invention also provides a method for determining a therapeutic effect on an allergic disease, comprising the step of measuring the concentration of a lipid metabolite in a biological sample of a subject.

The invention described herein relates to a method and kit for the diagnosis of antiphospholipid syndrome in patients, wherein a coagulation inhibitor and normal pooled plasma mixture reduce the factor deficiency effect of patient plasma, and coagulation inhibitor interference in patient plasma, and increases specificity and the sensitivity for detecting lupus anticoagulants in the patient's blood in a phospholipid-dependent clotting assay.

In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.

The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

The invention provides methods, compositions, and systems for diagnosis, prognosis, evaluation of status, and/or determination of treatment for pathological conditions.